Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations

被引:22
作者
Clark, SJ
Cabana, MD
Malik, T
Yusuf, H
Freed, GL
机构
[1] Univ Michigan, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA
[2] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
来源
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2001年 / 155卷 / 08期
关键词
D O I
10.1001/archpedi.155.8.915
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available. Objective: To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably). Design: A telephone survey of a random sample of 1000 US hospitals. Participants: Nurse managers, nursery directors, and staff nurses of the newborn nurseries. Main Outcome Measures: Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine. Results: Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7,1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants. Conclusions: Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.
引用
收藏
页码:915 / 920
页数:6
相关论文
共 9 条
[1]  
*AAP, 2001, MMWR-MORBID MORTAL W, V50, P94
[2]  
*AM AC FAM PHYS, 2000, POL STAT AM AC FAM P
[3]  
*AM AC PED PUBL HL, 1999, MMWR-MORBID MORTAL W, V48, P563
[4]  
[Anonymous], 1999, PEDIATRICS, V104, P568
[5]  
*CDCP, 1999, IMPL GUID IMM GRANT
[6]  
Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780
[7]  
Freed GL, 1996, J FAM PRACTICE, V42, P587
[8]  
FREED GL, 1994, PEDIATRICS, V93, P747
[9]   Limiting infant exposure to thimerosal in vaccines and other sources of mercury [J].
Halsey, NA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (18) :1763-1766